Fosamax (Alendronate Sodium) News and Research

RSS
Fosamax (alendronate sodium) is a drug that affects bone metabolism. It is used in treating osteoporosis and Paget's disease, and is being studied in the treatment of hypercalcemia (abnormally high levels of calcium in the blood) and in treating and reducing the risk of bone pain caused by cancer. Alendronate sodium belongs to the family of drugs called bisphosphonates.
Treatment with zoledronic acid effective in reducing fractures in women with postmenopausal osteoporosis

Treatment with zoledronic acid effective in reducing fractures in women with postmenopausal osteoporosis

Reclast found to cause abnormal heart rhythms

Reclast found to cause abnormal heart rhythms

Now OK to get prescription drugs from Canada, but is it really?

Now OK to get prescription drugs from Canada, but is it really?

More physicians now visit web sites to find information on brand-name prescription drugs

More physicians now visit web sites to find information on brand-name prescription drugs

Study assesses formularies across Medicare drug plans

Study assesses formularies across Medicare drug plans

Low bone density improved with jabs twice a year

Low bone density improved with jabs twice a year

Women with postmenopausal osteoporosis prefer once monthly to weekly treatment

Women with postmenopausal osteoporosis prefer once monthly to weekly treatment

Taking parathyroid hormone followed by a year on alendronate shows strong osteoporosis benefit

Taking parathyroid hormone followed by a year on alendronate shows strong osteoporosis benefit

Calcium crucial to benefits of osteoporosis drugs

Calcium crucial to benefits of osteoporosis drugs

Link found between bisphosphonates and a serious bone disease called osteonecrosis of the jaw

Link found between bisphosphonates and a serious bone disease called osteonecrosis of the jaw

Study indicates potential of alendronate and estrogen progression of osteoarthritis

Study indicates potential of alendronate and estrogen progression of osteoarthritis

50,000 people in the U.S. with cancer, multiple sclerosis, rheumatoid arthritis or hepatitis C will be eligible for a Medicare drug lottery

50,000 people in the U.S. with cancer, multiple sclerosis, rheumatoid arthritis or hepatitis C will be eligible for a Medicare drug lottery

New and Generic Drug Approvals from FDA

New and Generic Drug Approvals from FDA